ArticleFrontiers in cell and developmental biology2026
Curcumin-preconditioned bone marrow mesenchymal stem cell exosomes ameliorate postmenopausal osteoporosis by activating mitophagy in osteoblast-lineage cells.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmenopausal osteoporosis, driven by oxidative stress and impaired osteoblast function, remains a major health crisis with limited anabolic therapies. Exosomes from curcumin-preconditioned mesenchymal stem cells (MSCs) are promising cell-free therapeutics, yet their cellular targets and molecular mechanisms remain elusive. Methods: BMSCs were isolated, pretreated with curcumin, and exosomes were purified by ultracentrifugation. Exploratory scRNA-seq, Results: Curcumin pretreatment enhanced exosomal osteogenic potential without altering physicochemical properties. scRNA-seq identified osteoblast-lineage cells as major transcriptional responders. Cur-BMSC-Exo activated PINK1/Parkin-mediated mitophagy, eliminated damaged mitochondria, and restored mitochondrial function. This effect was abrogated by Mdivi1. Systemic Cur-BMSC-Exo administration significantly increased bone volume and trabecular thickness in OVX mice, whereas Mdivi1 abolished these benefits. Conclusion: Cur-BMSC-Exo ameliorates osteoporosis by activating mitophagy in osteoblast-lineage cells, offering a novel cell-free therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.